-14.6%
PCG vs MRNA
+27.0%
-41.5%
-39.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.3% | -3.4% | -0.9% | -4.2% |
| 7D | +6.5% | -10.1% | +16.5% | +6.6% |
| 30D | -16.7% | +126.7% | -143.5% | -18.4% |
| 3M | -14.2% | +184.1% | -198.3% | -17.1% |
| 6M | -21.5% | +143.3% | -164.7% | -23.6% |
| YTD | -11.2% | +359.9% | -371.0% | -17.0% |
| 1Y | -4.2% | +454.2% | -458.4% | -11.8% |
| All | -14.6% | +27.0% | -41.5% | -20.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling